| Literature DB >> 22807675 |
Beth Mann1, Tim van Opijnen, Jianmin Wang, Caroline Obert, Yong-Dong Wang, Robert Carter, Daniel J McGoldrick, Granger Ridout, Andrew Camilli, Elaine I Tuomanen, Jason W Rosch.
Abstract
Small noncoding RNAs (sRNAs) play important roles in gene regulation in both prokaryotes and eukaryotes. Thus far, no sRNA has been assigned a definitive role in virulence in the major human pathogen Streptococcus pneumoniae. Based on the potential coding capacity of intergenic regions, we hypothesized that the pneumococcus produces many sRNAs and that they would play an important role in pathogenesis. We describe the application of whole-genome transcriptional sequencing to systematically identify the sRNAs of Streptococcus pneumoniae. Using this approach, we have identified 89 putative sRNAs, 56 of which are newly identified. Furthermore, using targeted genetic approaches and Tn-seq transposon screening, we demonstrate that many of the identified sRNAs have important global and niche-specific roles in virulence. These data constitute the most comprehensive analysis of pneumococcal sRNAs and provide the first evidence of the extensive roles of sRNAs in pneumococcal pathogenesis.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22807675 PMCID: PMC3395615 DOI: 10.1371/journal.ppat.1002788
Source DB: PubMed Journal: PLoS Pathog ISSN: 1553-7366 Impact factor: 6.823
Figure 1Transcriptome map of S. pneumoniae TIGR4.
Compilation of the sRNA sequences yields a comprehensive transcriptome map of TIGR4. The outermost circle represents the chromosomal sequence of TIGR4 along with genomic coordinates. The sense and antisense transcripts are indicated by yellow and blue bars, respectively. Going inwards, the next pair of circles represents the position and orientation of the sRNAs identified in our study in addition to those predicted from previous reports. The red circle represents the total coverage of RNA based upon sequencing. The innermost circle indicates 60 bp windows of below average GC content (blue) and above average GC content (yellow).
sRNA identification and characteristics.
| Flanking Genes | |||||||||||||
| ID | Start | End | Size (nt) | Strand | Up | Down | Orientation | ΔG | Conservation | Previously identified | Confirmation | Motif/Family | Virulence |
| R1 | 171483 | 171628 | 146 | − | SP0178 | SP0179 | < > > | −46.9 | α γ | SN4 (a), srn029 (d) | Northern | ||
| R2 | 1221797 | 1221902 | 106 | − | SP1286 | SP1287 | > < < | −23.1 | α | No Signal | Motif 2 | ||
| R3 | 1275652 | 1275704 | 53 | − | SP1355 | SP1356 | < < < | −5.4 | α β | No, BOX element | |||
| R4 | 1351009 | 1351076 | 68 | − | SP1431 | SP1432 | > < > | −6.6 | α | No Signal | Blood | ||
| R6 | 1731557 | 1731734 | 178 | − | SP1820 | SP1821 | < < < | −42.37 | α | srn400 (d) | Northern | T-box | |
| R7 | 1791010 | 1791080 | 71 | − | SP1886 | SP1887 | > < < | −13 | α | Northern | Motif 4 | ||
| R8 | 1892645 | 1892717 | 73 | − | SP1988 | SP1989 | < < < | −11 | α | Northern | Nasopharynx,Blood | ||
| R9 | 1903548 | 1903638 | 91 | − | SP1999 | SP2000 | < < < | −19.5 | α | trn0935 (d) | Northern | ||
| R10 | 1987487 | 1987533 | 47 | − | SP2076 | SP2077 | < < < | −7.1 | α β γ | Northern | |||
| R11 | 2002164 | 2002195 | 32 | − | SP2093 | SP2094 | > < < | −2.1 | α γ | Northern | |||
| R12 | 1731041 | 1731440 | 400 | − | SP1818 | SP1819 | > < < | −111.39 | α | trn0830 (d) | Northern | Motif 1 & 5 | Nasopharynx, Blood |
| R13 | 623327 | 623372 | 46 | − | SP0649 | SP0650 | < < > | −8.7 | α γ | No Signal | |||
| R14 | 1034021 | 1034100 | 80 | − | SP1100 | SP1101 | > < < | −9.8 | α | qRT-PCR | Lung | ||
| R15 | 1214248 | 1214371 | 124 | − | SP1278 | SP1279 | < < < | −38.9 | α | SN42 (a), srn299 (d) | Previous Study | Pyr | |
| R16 | 1227703 | 1227744 | 42 | − | SP1292 | SP1293 | > < < | −3.9 | α γ | No Signal | Nasopharynx | ||
| R17 | 1277341 | 1277388 | 48 | − | SP1356 | SP1357 | < < < | −3.7 | α β | No Signal | |||
| R18 | 1364575 | 1364706 | 132 | − | SP1444 | SP1445 | > < < | −25.5 | α | Northern | |||
| R19 | 1390953 | 1391074 | 122 | − | SP1477 | SP1478 | < < < | −23.1 | α β | trn0663 (d) | Northern | ||
| R20 | 1455141 | 1455185 | 45 | − | SP1547 | SP1548 | < < < | −12.2 | α γ | Northern | |||
| R21 | 1461116 | 1461178 | 63 | − | SP1551 | SP1552 | < < > | −11.3 | α | SN44 (a), srn351 (d) | Previous Study | ||
| F1 | 91593 | 91664 | 72 | + | SP0085 | SP0086 | > > > | −17.1 | α | Northern | Motif 2 | ||
| F2 | 106533 | 106577 | 45 | + | SP0103 | SP0104 | > > < | −5.9 | α γ | No, BOX element | Motif 2 | Blood | |
| F3 | 117143 | 117248 | 106 | + | SP0115 | SP0116 | > > > | −21.97 | α | qRT-PCR | |||
| F4 | 118118 | 118166 | 49 | + | SP0116 | SP0117 | > > > | −11 | α γ | No Signal | |||
| F5 | 120678 | 120848 | 171 | + | SP0117 | SP0118 | > > > | −51.6 | α | trn0052 (d) | No, BOX element | Blood | |
| F6 | 130439 | 130495 | 57 | + | SP0129 | SP0130 | > > < | −19.9 | α | Northern | |||
| F7 | 209812 | 209917 | 106 | + | SP0239 | SP0240 | > > > | −18.9 | α | csRNA5, (b), SN35 (a), srn061 (d) | Northern | Lung, IN Challenge | |
| F8 | 228667 | 228720 | 54 | + | SP0256 | SP0257 | > > > | −14.5 | α | csRNA1, (b), (c), SN5 (a) | Previous Study | Motif 3 | |
| F9 | 231310 | 231359 | 50 | + | SP0257 | SP0258 | > > < | −6.4 | α β γ | No, BOX element | |||
| F10 | 284261 | 284317 | 57 | + | SP0311 | SP0312 | > > > | −17.9 | α | trn0157 (d) | Northern | Motif 3 | |
| F11 | 286614 | 286708 | 95 | + | SP0312 | SP0313 | > > < | −17.9 | α | Northern | |||
| F12 | 444624 | 444663 | 40 | + | SP0464 | SP0465 | > > < | −4.7 | α γ | No, BOX element | |||
| F13 | 470344 | 470441 | 98 | + | SP0493 | SP0494 | > > > | −32.1 | α | srn145 (d) | No, BOX element | ||
| F14 | 499570 | 499689 | 120 | + | SP0518 | SP0519 | > > > | −12.87 | α | Northern | Nasopharynx | ||
| F15 | 501732 | 501844 | 113 | + | SP0519 | SP0520 | > > < | −10.53 | α | (c), srn151 (d) | Northern | ||
| F16 | 528096 | 528162 | 67 | + | SP0560 | SP0561 | < > > | −7.3 | α | No, BOX element | Motif 1,5 | ||
| F17 | 530769 | 530895 | 127 | + | SP0564 | SP0565 | > > > | −7.3 | α | (c) | Previous Study | T-box | |
| F18 | 538437 | 538492 | 56 | + | SP0571 | SP0572 | > > < | −14.16 | α | Northern | Motif 4 | ||
| F19 | 543052 | 543150 | 99 | + | SP0575 | SP0576 | > > > | −29.23 | α | Northern | |||
| F20 | 547541 | 547749 | 209 | + | SP0578 | SP0579 | > > > | −49.72 | α β | srn157 (d) | Northern | Nasopharynx, IN Challenge | |
| F21 | 557415 | 557447 | 33 | + | SP0586 | SP0587 | > > < | −1.3 | α | No, BOX element | |||
| F22 | 592573 | 592712 | 140 | + | SP0625 | SP0626 | > > > | −36.8 | α | qRT-PCR | IN Challenge | ||
| F23 | 603204 | 603346 | 143 | + | SP0640 | SP0641 | > > > | −28.34 | α | trn0329 (d) | No, BOX element | ||
| F24 | 610528 | 610660 | 133 | + | SP0641 | SP0642 | > > < | −32.25 | α β | Northern | Motif 4 | Nasopharynx | |
| F25 | 623244 | 623345 | 102 | + | SP0649 | SP0650 | < > < | −32.8 | α | SN11 (a), trn0332 (d) | Northern | Blood, IN Challenge | |
| F26 | 668007 | 668112 | 106 | + | SP0700 | SP0701 | < > > | −31.18 | α | SN12 (a) | Northern | Pyr | |
| F27 | 684656 | 684797 | 142 | + | SP0718 | SP0719 | > > > | −31.95 | α | trn0358 (d) | No, BOX element | TPP | Blood |
| F28 | 709064 | 709122 | 59 | + | SP0749 | SP0750 | > > > | −26.3 | α | No, BOX element | |||
| F29 | 743792 | 743828 | 37 | + | SP0788 | SP0789 | > > > | −9.2 | α | No, BOX element | Lung | ||
| F30 | 743886 | 743933 | 48 | + | SP0788 | SP0789 | > > > | −6.2 | α γ | No, BOX element | Motif 5 | ||
| F31 | 810811 | 810862 | 52 | + | SP0863 | SP0864 | < > > | −10.4 | α β | (c) | Previous Study | ||
| F32 | 821924 | 822271 | 348 | + | SP0873 | SP0874 | > > < | −81.41 | α β | SN16 (a), srn226 (d) | Previous Study | tmRNA | Lung, IN Challenge |
| F33 | 863736 | 863818 | 83 | + | SP0910 | SP0911 | > > < | −17.38 | α | (c) | Previous Study | Motif 2 | |
| F34 | 907218 | 907312 | 95 | + | SP0958 | SP0959 | > > > | −34.2 | α | (c), SN40 (a), srn239 (d) | Previous Study | ||
| F35 | 909029 | 909169 | 141 | + | SP0962 | SP0963 | > > > | −38.03 | α | srn241 (d) | Northern | ||
| F36 | 941435 | 941487 | 53 | + | SP1000 | SP1001 | > > > | −16.1 | α | Northern | |||
| F38 | 956782 | 956928 | 147 | + | SP1012 | SP1013 | > > > | −45.94 | α | ©, srn254 (d) | Previous Study | Nasopharynx | |
| F39 | 972498 | 972607 | 110 | + | SP1029 | SP1030 | > > > | −18.52 | α γ | qRT-PCR | |||
| F40 | 1063101 | 1063151 | 51 | + | SP1128 | SP1129 | > > < | −17.3 | Northern | Motif 2 | |||
| F41 | 1071112 | 1071214 | 103 | + | SP1142 | SP1143 | > > > | −33.08 | srn277 (d) | Northern | Nasopharynx, Blood, IN Challenge | ||
| F42 | 1093532 | 1093614 | 83 | + | SP1157 | SP1158 | > > < | −23.2 | α | No Signal | |||
| F43 | 1216148 | 1216246 | 99 | + | SP1281 | SP1282 | > > > | −27.8 | α | Northern | |||
| F44 | 1220366 | 1220460 | 95 | + | SP1285 | SP1286 | > > > | −20.74 | α | Northern | IN Challenge | ||
| F45 | 1408204 | 1408275 | 72 | + | SP1499 | SP1500 | > > < | −22.1 | α | qRT-PCR | Motif 2 & 3 | Blood | |
| F46 | 1454220 | 1454277 | 58 | + | SP1546 | SP1547 | > > < | −20.6 | α | No, BOX element | |||
| F47 | 1530016 | 1530100 | 85 | + | SP1629 | SP1630 | > > > | −12.55 | α β | SN24 (a) | Northern | ||
| F48 | 1778293 | 1778427 | 135 | + | SP1872 | SP1873 | > > < | −38.3 | α | Northern | Motif 1 & 2 & 3 | IN Challenge | |
| F49 | 2026337 | 2026403 | 67 | + | SP2112 | SP2113 | > > < | −21.9 | α | No, BOX element | Motif 2 | ||
| F50 | 2085887 | 2085994 | 108 | + | SP2168 | SP2169 | > > < | −27.1 | α | No, BOX element | Motif 2 & 3 | ||
| F51 | 2133001 | 2133045 | 45 | + | SP2213 | SP2214 | < > < | −9.9 | α γ | Northern | Motif 3 | Nasopharynx | |
| F52 | 40336 | 40380 | 45 | + | SP0041 | SP0042 | > > > | −16.8 | α γ | No, BOX element | Nasopharynx | ||
| F53 | 588512 | 588590 | 79 | + | SP0619 | SP0620 | > > < | −12.62 | α | Northern | |||
| F54 | 1424517 | 1424756 | 240 | + | SP1516 | SP1517 | < > < | −64.4 | α | No, BOX element | Motif 1,5 | ||
| F55 | 1696066 | 1696162 | 97 | + | SP1777 | SP1778 | > > < | −11.97 | α | Northern | Motif 1 | ||
| F56 | 158993 | 159090 | 98 | + | SP0162 | SP0163 | > > > | −7.7 | Northern | ||||
| F57 | 553923 | 553982 | 60 | + | SP0584 | SP0585 | > > > | −10.6 | α | No Signal | |||
| F58 | 716443 | 716473 | 31 | + | SP0757 | SP0758 | > > > | −11.2 | α β γ | No Signal | |||
| F59 | 869510 | 869591 | 82 | + | SP0915 | SP0916 | < > > | −24.7 | α | SN20 (a), srn235 (d) | Previous Study | ||
| F60 | 950115 | 950165 | 51 | + | SP1004 | SP1005 | > > > | −2.8 | α | trn0485 (d) | No Signal | Lung | |
| F61 | 972327 | 972384 | 58 | + | SP1029 | SP1030 | > > > | −8.6 | α | Northern | |||
| F62 | 995726 | 995787 | 62 | + | SP1059 | SP1060 | > > > | −24.5 | Northern | Lung | |||
| F63 | 1090060 | 1090100 | 41 | + | SP1154 | SP1155 | > > > | −1.5 | α γ | No Signal | Nasopharynx | ||
| F64 | 1118416 | 1118462 | 47 | + | SP1179 | SP1180 | > > > | −1.7 | α γ | No Signal | Nasopharynx | ||
| F65 | 1350946 | 1351012 | 67 | + | SP1431 | SP1432 | > > > | −19.2 | α | No Signal | Motif 2 | Nasopharynx | |
| F66 | 2086087 | 2086325 | 239 | + | SP2168 | SP2169 | > > < | −73.9 | α | srn502 (d) | Northern | ||
| F67 | 2086466 | 2086584 | 119 | + | SP2168 | SP2169 | > > < | −25.5 | α | srn503 (d) | Northern | ||
| F68 | 2132994 | 2133050 | 57 | + | SP2213 | SP2214 | > > < | −11.3 | α | No Signal | Motif 3 |
Columns from left to right represent the identification of the sRNA (ID), the coordinates on the TIGR4 genome to which the sRNA mapped (Start, End), the predicted size, the strand that encodes the sRNA, the genes immediately flanking the sRNA, the orientation of the sRNA and flanking genes (> = forward, < = reverse, sRNA is in center), the predicted free energy of the sRNA (delta G), the conservation of the sRNA with α = homologs in Streptococcus pneumoniae, β = conserved amongst streptococci, γ = conserved in other gram-positive bacteria, whether sRNA was previously identified by (a) Kumar et al., 2010, (b) Halfman et al, 2007, (c) Livny et al., 2006 or (d) Acebo et al 2012, and the method of confirmation. Conserved motifs or Rfam assignments are indicated in the Motif/Family column. If deletion of the sRNA had an effect on virulence identified by Tn-seq, the host site is indicated in the final column. If the sRNA was attenuated by IN challenge, this is also indicated in the final column.
Figure 2Flowchart of the order and types of analyses for identification and characterization of sRNAs.
The order of the experiments performed, along with the corresponding figures and tables is outlined.
Figure 3Involvement of many sRNAs in pathogenesis.
A. Mice were challenged intranasally with the parental TIGR4 strain (filled circles) or the indicated sRNA mutant (open squares). Data represents the overall survival of at least 10 mice from 2 independent experiments. P<0.05 for all the mutants shown by Mantel-Cog log rank test. B. Northern blots of the sRNAs involved in pathogenesis arranged adjacent to the corresponding deletion mutant (top panels). Loading controls against gyrA are shown in the bottom panels. The F22 sRNA was not detectable by Northern, and hence the Ct values for the qRT-PCR for F22 and gyrA in both the TIGR4 and ΔF22 are presented.
Tn-seq analysis of the ability of sRNA mutants to survive in different host niches.
| sRNA | Host Tissue | Fitness | p-value |
| F7 | Lung | 0.49 | <0.001 |
| F29 | Lung | 1.15 | 0.005 |
| F32 | Lung | 0.08 | <0.001 |
| F60 | Lung | 0.54 | 0.016 |
| F62 | Lung | 0.64 | 0.004 |
| R14 | Lung | 0.53 | 0.02 |
| srn061 | Lung | 0.49 | <0.001 |
| srn157 | Lung | 0.53 | <0.008 |
| srn218 | Lung | 0.15 | <0.001 |
| srn226 | Lung | 0.08 | <0.001 |
| srn235 | Lung | 0.05 | <0.001 |
| srn368 | Lung | 0.41 | <0.008 |
| srn400 | Lung | 0.31 | <0.001 |
| trn0012 | Lung | 0.53 | <0.001 |
| trn0052 | Lung | 0.64 | <0.008 |
| trn0634 | Lung | 0.17 | <0.001 |
| SN1 | Lung | 0.62 | <0.001 |
| SN12 | Lung | 0.49 | <0.001 |
| SN16 | Lung | 0.09 | <0.001 |
| SN2 | Lung | 0.75 | <0.001 |
| SN20 | Lung | 0.05 | <0.001 |
| SN22 | Lung | 0.26 | <0.001 |
| SN26 | Lung | 0.43 | <0.005 |
| SN31 | Lung | 0.62 | <0.001 |
| SN32 | Lung | 0.08 | <0.001 |
| SN46 | Lung | 0.81 | <0.005 |
| SN5 | Lung | 0.34 | <0.001 |
| SN6 | Lung | 0.66 | <0.005 |
| F14 | Nasopharynx | 0.139 | <0.001 |
| F20 | Nasopharynx | 0.43 | 0.012 |
| F24 | Nasopharynx | 0 | 0.013 |
| F38 | Nasopharynx | 0 | 0.013 |
| F41 | Nasopharynx | 0 | 0.013 |
| F51 | Nasopharynx | 0.46 | 0.056 |
| F52 | Nasopharynx | 0 | 0.013 |
| F63 | Nasopharynx | 1.14 | <0.001 |
| F64 | Nasopharynx | 0 | 0.013 |
| F66 | Nasopharynx | 0 | 0.013 |
| R08 | Nasopharynx | 0 | 0.013 |
| R12 | Nasopharynx | 0 | 0.013 |
| R16 | Nasopharynx | 0.42 | 0.02 |
| srn142 | Nasopharynx | 0 | <0.003 |
| srn254 | Nasopharynx | 0 | <0.003 |
| srn277 | Nasopharynx | 0 | <0.003 |
| srn502 | Nasopharynx | 0 | <0.003 |
| srn502 | Nasopharynx | 0 | <0.003 |
| trn0156 | Nasopharynx | 0 | <0.003 |
| trn0760 | Nasopharynx | 0 | <0.003 |
| trn0830 | Nasopharynx | 0 | <0.003 |
| SN27 | Nasopharynx | 0.34 | <0.01 |
| SN30 | Nasopharynx | 0 | <0.002 |
| SN39 | Nasopharynx | 0 | <0.002 |
| SN46 | Nasopharynx | 0 | <0.002 |
| SN50 | Nasopharynx | 1.13 | <0.002 |
| F2 | Blood | 0.533 | 0.188 |
| F5 | Blood | 0 | 0.005 |
| F25 | Blood | 0.824 | 0.007 |
| F27 | Blood | 0.895 | 0.001 |
| F41 | Blood | 0.334 | 0.002 |
| F45 | Blood | 0.836 | 0.003 |
| R04 | Blood | 0.273 | 0.006 |
| R08 | Blood | 0.747 | 0.014 |
| R12 | Blood | 0.742 | 0.003 |
| srn279 | Blood | 1.34 | <0.003 |
| trn1025 | Blood | 1.22 | <0.003 |
| trn0830 | Blood | 0.74 | <0.005 |
| trn0012 | Blood | 0 | <0.003 |
| trn0052 | Blood | 0 | <0.003 |
| SN11 | Blood | 0.82 | <0.01 |
| SN27 | Blood | 0.86 | <0.01 |
| SN38 | Blood | 0 | <0.002 |
| SN46 | Blood | 1.19 | <0.002 |
Transposon mutant libraries were used to determine the ability of sRNAs to survive when inoculated into the nasopharynx or lung or to establish bacteremia in the blood following intraperitoneal injection of bacteria. Fitness value of 1.0 indicates no fitness benefit or defect compared to TIGR4. Values <1.0 indicate a fitness defect in the respective model while values >1.0 indicate a relative fitness benefit. When no mutants were present in the input pool, the sRNA was eliminated from the analysis while a fitness value of 0 indicated a mutant which was present in the input sample but was not recovered in the output pool.
Figure 4Confirmation of tissue-specific fitness defects of sRNA mutants identified as attenuated by Tn-seq.
Mice were challenged with the sRNA mutants and parental TIGR4 in a competitive index model of infection whereby equivalent CFUs of the wild type and each mutant are administered simultaneously to a specific body site and the bacterial density is measured 24 hours post infection by differential plating. The competitive index of the respective mutants in the blood (A), nasophaynx (B), and lungs (C) are indicated. Competitive index of 1 represents equivalent amounts of wild type and mutant bacteria were recovered. Each data point represents a single mouse. All experiments were performed in duplicate. P<0.05 by Mann-Whitney for all sRNA mutants.
Figure 5Proteomic analysis of attenuated sRNA mutants.
Duplicate 2D gels of protein lysates prepared from the parental TIGR4 strain and the eight attenuated sRNA mutants were run and the individual protein spots were quantified (example shown in Figure S6 in Text S1). A representative subset of identified proteins showing altered expression in the ΔF20 strain compared to TIGR4 is shown in the upper panel (green circles). The number of polypeptide spots altered in each mutant vs TIGR4 by a fold increase of >1.7 and p value<0.05 (t-test) or a fold increase of >3.0 are enumerated in the bottom panel.